Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour

被引：7
作者：
Acres, Bruce [2 ]
Lacoste, Gisele [1 ]
Limacher, Jean-Marc [1 ]
机构：
[1] Transgene SA, Dept Med Affairs, 400 Blvd Gonthier Andernach,Parc Innovat CS80166, F-67405 Illkirch Graffenstaden, France
[2] Bruce Acres Consulting, Strasbourg, France
来源：
CANCER VACCINES | 2017年 / 405卷
关键词：
CELL LUNG-CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; BLP25 LIPOSOME VACCINE; PHASE-I TRIAL; MUC1; IMMUNOTHERAPY; PANCREATIC-CANCER; IMMUNE-RESPONSES; DENDRITIC CELLS; BLADDER-CANCER; CORE-PROTEIN;
D O I：
10.1007/82_2015_429
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Several approaches to antigen-specific immunotherapy of cancer antigen-specific immunotherapy of cancer have been tested clinically. In this chapter, we will describe studies done with the antigen MUC1. Tested MUC1 therapeutic vaccines include the following: monoclonal antibodies (MAbs) specific for MUC1; synthetic and recombinant polypeptides from the protein sequence of MUC1; dendritic cells carrying MUC1; RNA and DNA vaccinations; and recombinant viruses carrying the MUC1 DNA sequence. Chemotherapy of cancer aims to be toxic to the cancer cells with manageable side effects to the patient. In contrast, antigen-specific immunotherapy of cancer aims to treat the patient, such that the patient is then able to control and eventually eliminate their cancer cells. It is therefore important to know the immune status of each cancer patient prior to therapy.
引用
收藏
页码：79 / 97
页数：19
相关论文
共 17 条
  • [1] ImMucin: A novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors
    Kovjazin, Riva
    Volovitz, Ilan
    Kundel, Yulia
    Rosenbaum, Eli
    Medalia, Gal
    Horn, Galit
    Smorodinsky, Nechama I.
    Brenner, Baruch
    Carmon, Lior
    VACCINE, 2011, 29 (29-30) : 4676 - 4686
  • [2] Adoptive immunotherapy for pancreatic cancer: Cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1
    Kawaoka, Toru
    Oka, Masaaki
    Takashima, Motonari
    Ueno, Tomio
    Yamamoto, Koutaro
    Yahara, Noboru
    Yoshino, Shigefumi
    Hazama, Shoichi
    ONCOLOGY REPORTS, 2008, 20 (01) : 155 - 163
  • [3] The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours
    Yang, H.
    Cho, N. -H.
    Seong, S. -Y.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 158 (02) : 174 - 185
  • [4] MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells
    Wright, Stephen E.
    Rewers-Felkins, Kathleen A.
    Quinlin, Imelda S.
    Fogler, William E.
    Phillips, Catherine A.
    Townsend, Mary
    Robinson, William
    Phllip, Ramila
    IMMUNOLOGICAL INVESTIGATIONS, 2008, 37 (03) : 215 - 225
  • [5] Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma
    Kodama, H
    Suzuki, M
    Katayose, Y
    Shinoda, M
    Sakurai, N
    Takemura, S
    Yoshida, H
    Saeki, H
    Ichiyama, M
    Tsumoto, K
    Asano, R
    Kumagai, I
    Imai, K
    Hinoda, Y
    Matsuno, S
    Kudo, T
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (10) : 539 - 548
  • [6] L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice
    Mehta, Neelima R.
    Wurz, Gregory T.
    Burich, Rebekah A.
    Greenberg, Brittany E.
    Griffey, Stephen
    Gutierrez, Audrey
    Bell, Katie E.
    McCall, Jamie L.
    Wolf, Michael
    DeGregorio, Michael
    CLINICAL CANCER RESEARCH, 2012, 18 (10) : 2861 - 2871
  • [7] Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer
    Rochlitz, C
    Figlin, R
    Squiban, P
    Salzberg, M
    Pless, M
    Herrmann, R
    Tartour, E
    Zhao, YX
    Bizouarne, N
    Baudin, M
    Acres, B
    JOURNAL OF GENE MEDICINE, 2003, 5 (08) : 690 - 699
  • [8] A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1
    R W Wilkinson
    E L Ross
    A E Lee-MacAry
    R Laylor
    J Burchell
    J Taylor-Papadimitriou
    D Snary
    British Journal of Cancer, 2000, 83 : 1202 - 1208
  • [9] A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1
    Wilkinson, RW
    Ross, EL
    Lee-MacAry, AE
    Laylor, R
    Burchell, J
    Taylor-Papadimitriou, J
    Snary, D
    BRITISH JOURNAL OF CANCER, 2000, 83 (09) : 1202 - 1208
  • [10] Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model
    Mony, Jyothi Thyagabhavan
    Zhang, Lixin
    Ma, Tianzhou
    Grabosch, Shannon
    Tirodkar, Tejas S.
    Brozick, Joan
    Tseng, George
    Elishaev, Esther
    Edwards, Robert P.
    Huang, Xin
    Vlad, Anda M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (09) : 1095 - 1108
12